Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment

American Journal of Drug and Alcohol Abuse

Volumn 39, Issue 2, 2013, Pages 80-85

  Douglas Bruce, R ^a   Moody, David E ^b   Chodkowski, Diane ^a   Andrews, Laurie ^a   Fang, Wenfang B ^b   Morrison, Jerdravee ^b   Parsons, Theresa L ^c   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Buprenorphine naloxone; HIV AIDS; Pharmacokinetics; Raltegravir; Substance abuse

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; NORBUPRENORPHINE; RALTEGRAVIR;

ABDOMINAL CRAMP; ADULT; ANTIVIRAL THERAPY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; COMMON COLD SYMPTOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LOWER ABDOMINAL PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPIATE ADDICTION; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SUBSTANCE ABUSE; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN;

ADULT; ANTIVIRAL AGENTS; BUPRENORPHINE; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; GLUCURONOSYLTRANSFERASE; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; PYRROLIDINONES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84874166524     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2013.764885     Document Type: Article

References (32)

1. Bruce RD, Altice FL, Friedland GH. HIV Disease among substance users: Treatment issues. In Global HIV/AIDS Medicine. Volberding P. ed. New York, NY: Elsevier, 2007.
2. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS 2007; 21(8):564-574. (Pubitemid 350194958)
3. Kerr T, Wodak A, Elliott R, Montaner JS, Wood E. Opioid substitution and HIV/AIDS treatment and prevention. Lancet 2004; 364(9449):1918-1919. (Pubitemid 39574577)
4. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis 2006; 43(Suppl. 4): S178-S183. (Pubitemid 44901885)
5. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 2006; 42(5):716-721. (Pubitemid 43271389)
6. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: Results from a multisite study. J Acquir Immune Defic Syndr 2011; 56(Suppl. 1):S22-S32.
7. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5):563-572.
8. Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43(Suppl. 4): S216-S223. (Pubitemid 44901889)
9. Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 2009; 105(3):234-239.
10. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. Aids 2002; 16(5):767-774. (Pubitemid 34274467)
11. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13(8):957-962. (Pubitemid 29240191)
12. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21(1):149-179, i.x. (Pubitemid 46719806)
13. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrugresistant virus: A phase II randomised controlled trial. Lancet 2007; 369(9569):1261-1269. (Pubitemid 46553846)
14. Iwamoto M, Kassahun K, Troyer MD, Hanley WD, Lu P, Rhoton A, Petry AS, Ghosh K, Mangin E, Denoia EP, Wenning LA, Stone JA, Gottesdiener KM, Wagner JA. Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation. J Clin Pharmacol 2008; 48(2):209-214.
15. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83(2):293-299.
16. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol 2011; 51(10):1376-1402.
17. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12(5):577-581. (Pubitemid 14020828)
18. Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 2009; 3(2):101-107.
19. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010; 38(1):40-45.
20. Brown SM, Holtzman M, Kim T, Kharasch ED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 2011; 115(6):1251-1260.
21. Huang P, Kehner GB, Cowan A, Liu-Chen L-Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297(2):688-695. (Pubitemid 32378001)
22. Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272(2):505-510.
23. Fang WB, Chang Y, McCance-Katz EF, Moody DE. Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatographyelectrospray ionization- tandem mass spectrometry. J Anal Toxicol 2009; 33(8):409-417.
24. Brainard DM, Wenning LA, Stone JA, Wagner JA, Clinical Pharmacology IM. Profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol 2011; 10:1376-1402.
25. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13(3):293-308. (Pubitemid 17143298)
26. Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19(15):1635-1641. (Pubitemid 41502676)
27. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857(1):15-24. (Pubitemid 47362852)
28. Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionizationtandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002; 306(1):31-39. (Pubitemid 34722013)
29. Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008; 52(9):3253-3258.
30. Hanley WD, Wenning LA, Moreau A, Kost JT, Mangin E, Shamp T, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53(7):2752-2755.
31. Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br J Clin Pharmacol 2010; 69(5):475-483.
32. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampininduced methadone withdrawal. N Engl J Med 1976; 294 (20):1104-1106.